In order to assess the accuracy of Scottish cancer registration data, a random sample of 2,200 registrations, attributed to the year 1990, was generated. Relevant medical records were available for review in 2,021 (92%) cases. Registration details were reabstracted from available records and compared with data in the registry. Discreancies in identifying items of data (surname, forename, sex and date of birth) were found in 3.5% of cases. Most were trivial and would not disturb record linkage. Discrepancy rates of 7.1% in post code of residence at the time of diagnosis (excluding differences arising through boundary changes), 11.0% in anniversary date (excluding differences of 6 weeks or less), 7.7% in histological verification status, 5.4% in ICD-9 site codes (the first three digits) and 14.5% in ICD-O morphology codes (excluding 'inferred' morphology codes) were recorded. Overall, serious discrepancies were judged to have occurred in 2.8% of cases. In many respects, therefore, Scottish cancer registration data show a high level of accuracy that compares favourably to the reported accuracy of the few other cancer registries undertaking such analyses.
The value of cancer registration data is largely dependent on their accuracy and completeness. If available data are to be interpreted with confidence, they need to be (and be seen to be) of high quality (Joslin. 1990; Skeet. 1991) . Although several studies in Scotland have examined the accuracy of cancer registration data. these have either been tumour specific (Glass et al.. 1987 : Gray et al.. 1987 . Health Board based (Lapham & Waugh. 1992) or both (Baijal et al., 1989) . The purpose of our study was to assess the overall accuracy of Scottish cancer registration data.
The organisation of cancer registration in Scotland has been described elsewhere (SHHD. 1990 ). In summary. five regional registries collect data usually denrved from a source document compiled by hospital discharge data-coding clerks or from a histopathology report. In addition, the Registrar General for Scotland supplies a quarterly listing of people who have had any mention of cancer on their death certificates.
Tumours eligible for registration are: all malignant neoplasms (ICD-9 140-208), carcinoma in situ (ICD-9 230-234), neoplasms of uncertain behaviour (ICD-9 235-238) and neoplasms of unspecified nature . Beyond this, eligibility criteria for registration of a tumour are implicit rather than explicitly defined. However, it is generally accepted that, for a tumour to be included in the Scottish data set, the patient should have been resident in Scotland for at least 6 months before diagnosis. from death certificates only (DCOs) (Table  III) .
Although the proportions of all types of site discrepancies varied significantly by regional registry (15-35%, P <0.001), there were no sigificant differences in the proportions of first three-digit site code discrepancies. availability of medical records compares favourably with a similar study (West, 1976) in which only 81% of medical records were traced. In view of the policy of some health boards of destroying primary care records of patients deceased for more than 2 or 3 years, it is not surprising that a higher proportion of DCO registrations had unobtainable records. The significant regional difference in total record availability arose because of lower than average availability in two major health boards (86% and 89%).
Reabstracted details may not represent everyone's interpretation of the information held in patients' medical records. Indeed, information in medical records, even histopathological diagnoses, may sometimes be invalid (Saksela & Rintala, 1968; Symmers, 1968; Hakama et al., 1973; Sax6n, 1979; Gray et al., 1987; Ullin et al., 1990) . Nevertheless, the reabstracted record method is regarded as the most objective way of evaluating the accuracy of cancer registration data (Parkin et al., 1992) .
Comparison with other studies Use of differing selection criteria and different ways of presenting results means that comparisons with other studies are not always straightforward. Furthermore, since the discrepancy rate (except, perhaps, in identifying data) seems to vary according to site (West, 1976; Polissar et al., 1984) , comparisons with single-site studies should be viewed with caution. In this study, apart from cases for whom medical records could not be retrieved, all patients were included in the analysis of each item of data (and only rarely were relevant details absent from available medical records). Thus, the rate of discrepancies might be expected to be higher than in other studies which exclude certain categories of patient (such as DCOs).
Identifying data
The low rate of surname discrepancies (0.9%) is similar to the 0.8% found by West (1976) in South Wales, although twice as many first forename discrepancies were found in the Welsh study (2.1%) as in this one (1.0%). Discrepancies in gender were not recorded in Wales, but in two other studies the discrepancy rate was higher at 1.0% (Polissar et al., 1984) and 0.5% (Kee et al., 1992) than in Scotland (0.4%). Rates of date of birth discrepancies reported from other studies have been 11.2% (West, 1976) , 4% (Polissar et al., 1984) and 7% (Gulliford et al., 1993) , all higher than in Scotland (1.3%).
More than one version (but including the registered version) of surname spelling, forename spelling and date of birth were found in the medical records of 2.2%, 2.3% and 2.6% of cases respectively. Since these were not counted as discrepancies, the true rate of inaccuracy in surname, forename and date of birth may have been underestimated in this study.
'Date treatment commenced' (anniversary date) The choice of anniversary date has three important implications: firstly, it determines to which year's registration data the neoplasm is allocated; secondly, it affects the caculation of age at diagnosis; and, thirdly, it affects the calculation of survival figures.
In this study, only 5% of registrations were reassigned to a different year of incidence. Equivalent figures for other studies were 7.6% (West, 1976) , 0.5% of a sample of leukaemia cases (Glass et al., 1987) , 1.6% of a sample of leukaemia cases (Baijal et al., 1989) , 13.4% of a sample of breast cancers (Kee et al., 1992) and 4.8% of a sample of bladder cancers (Gulliford et al., 1993) .
Discrepancies in anniversary date were particularly evident in the case of non-melanoma skin tumours. This seemed to depend on whether day case procedures had been mrgarded as admissions to hospital. If, as in this study, they were not, the (often much earlier) date of first attendance at out-patient clinic was chosen as the anniversary date. The potential for allocating quite different anniversary dates to non-melanoma skin tumours may explain why, in terms of the proportion of reabstacted records given anniversary dates within 6 weeks of those originally recorded, regional variation became insignificant when non-melanoma skin tumours were excluded from the analysis. Nevertheless, the observed regional variation for all tumour sites suggests the use of variable criteria to choose the anniversary date. Since some cancer patients never receive treatment for their disease, we believe that the term 'date treatment commenced' is misleading and should be abandoned in favour of 'date of diagnosis' (which is theoretically applicable to all patients). Rules governing the choice of this date need to be expanded, perhaps in accordanice with those outlined for 'incidence date' in . Random misclassification to adjacent years is unlikely to substantially distort time trends over a period of years, providing it occurs to a similar extent from year to year. However, tumours registered to 1990 that were actually incident in the years before 1989 have greater potential to adversely affect survival figures. Fortunately, such registrations formed only 1.3% of the total study population.
Histological verification status
There is some evidence of confusion about what constitutes histological verification. As with 'date treatment commenced', we believe that this stems partly from inadequate guidelines but perhaps also from difficulties in achieving uniformity of practice across five functionally independent regional registries. An ideal solution would be to collect the 'most valid basis of diagnosis' as outlined in MacLennan (1991). This was suggested during a recent review of the Scottish Cancer Registration System (SHHD, 1990) and is presently under consideration.
On occasion, the relevant pathology report was not in the case notes of the registering hospital because the diagnosis had already been made at a different hospital (and should have been registered there). In such cases, histological verification status (and, where available, morphology) had to be derived from clinical notes or correspondence contained in the medical records. Anniversary date was similarly difficult to derive with precision for some of these patients. Since a considerable proportion of patients seen at tertiary referral centres have presumably been diagnosed at other hospitals, rgistrations by tertiary centres imply a possible failure of registration mechanisms in other hospitals and must raise some concerns about completeness of case ascertainment generally (Benn et al., 1982) .
Site discrepancies At first glance, a 32% rate of site coding discrepancies is disappointing. Rates reported from other studies have been 16% (West, 1976) , 38% of a sample of oral cancers (Franklin, 1984) , 27% (Polissar et al., 1984) and 26.4% (Lapham & Waugh, 1992) . The most important discrepancies are those affecting the first three digits of the site code. In this study, only 5.4% of registrations had discrepancies at this level. Equivalent figures reported in previous studies have been 6.3% (West, 1976) , 30% of a sample of oral cancers (Franklin, 1984) , 7% (Polissar et al., 1984) and 7.1% (Lapham & Waugh, 1992) .
Predictably, more than half (61%) of the observed site discrepancies in this study were the result of failure to code to a specific subsite. Sometimes, however, the subsite is not explicitly stated in the medical records or, as noted elsewhere (Lapham & Waugh, 1992) Variation bY regional registry Although references to variation by regional registry have been made throughout the presentation of results, it should be remembered that this study was not primarily designed to measure such variation (in which case, a stratified sample would have been drawn). Nevertheless, the fact that regional variation in the level of discrepancies was observed could have implications for studies of geographical variations in incidence and survival. However. it is reassuring to note that there was no evidence of significant regional variation interms of site code (the first three digits) nor (for malignant neoplasms excluding non-melanoma skin tumours) anniversary date (within 6 weeks). Furthermore. when regional vranation in discrepancy rates were observed. no single registry performed consistently poorly.
Conclusion
In many respects. Scottish Cancer Registration data show a high level of accuracy. This should be reassuring to those involved in exploratory epidemiological studies of commonly occurring cancers and in the assessment of needs for cancer services. However, we have identified a number of problem areas which are currently being considered in the context of a wider review of the structure and mechanisms of cancer registration in Scotland.
(A more detailed account of this study and its results is available, on request, from the authors.)
